Trial Profile
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Avacopan (Primary) ; Azathioprine; Cyclophosphamide; Cyclophosphamide; Mycophenolate; Prednisone; Rituximab
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Registrational; Therapeutic Use
- Acronyms ADVOCATE
- Sponsors ChemoCentryx
- 18 Nov 2023 Results of subgroup analysis assessing the safety and efficacy of Avacopan in patients with ANCA-associated vasculitis receiving rituximab published in the Annals of the Rheumatic Diseases.
- 15 Nov 2023 Results of post-hoc analysis assessing effect of avacopan on urinary albumin:creatinine ratio in patients with antineutrophil cytoplasmic autoantibody presented at the ACR Convergence 2023.
- 15 Nov 2023 Results evaluating the efficacy and safety of avacopan in patients in the RTX stratum , presented at the ACR Convergence 2023